Lead Product(s): Pegadricase
Therapeutic Area: Musculoskeletal Product Name: SEL-212
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
The phase 3 DISSOLVE clinical programme a randomized double-blind, placebo-controlled study in which SEL-212 will be evaluated at two doses of ImmTOR, and one dose of pegadricase in both studies.